3 Stocks Pulling The Health Services Industry Downward

Two out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading down 19 points (-0.1%) at 15,282 as of Wednesday, July 10, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 1,222 issues advancing vs. 1,685 declining with 126 unchanged.

The Health Services industry currently sits down 0.1% versus the S&P 500, which is down 0.1%. Top gainers within the industry include Intuitive Surgical ( ISRG), up 1.6%, Agilent Technologies ( A), up 1.7%, Quest Diagnostics ( DGX), up 1.4%, CareFusion ( CFN), up 1.4% and Laboratory Corporation of America Holdings ( LH), up 1.3%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3. Bio-Reference Labs ( BRLI) is one of the companies pushing the Health Services industry lower today. As of noon trading, Bio-Reference Labs is down $2.21 (-7.7%) to $26.46 on heavy volume. Thus far, 727,867 shares of Bio-Reference Labs exchanged hands as compared to its average daily volume of 339,300 shares. The stock has ranged in price between $26.28-$28.24 after having opened the day at $28.22 as compared to the previous trading day's close of $28.67.

Bio-Reference Laboratories, Inc. provides clinical laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases primarily in the greater New York metropolitan area. Bio-Reference Labs has a market cap of $821.0 million and is part of the health care sector. Shares are up 3.7% year to date as of the close of trading on Tuesday. Currently there are 3 analysts that rate Bio-Reference Labs a buy, 1 analyst rates it a sell, and none rate it a hold.

TheStreet Ratings rates Bio-Reference Labs as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Bio-Reference Labs Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Catamaran ( CTRX) is down $0.62 (-1.3%) to $47.25 on average volume. Thus far, 1.2 million shares of Catamaran exchanged hands as compared to its average daily volume of 1.9 million shares. The stock has ranged in price between $46.87-$47.96 after having opened the day at $47.91 as compared to the previous trading day's close of $47.87.

Catamaran Corporation provides pharmacy benefit management (PBM) services and healthcare information technology (HCIT) solutions to the healthcare benefits management industry in North America. The company operates in two segments: PBM and HCIT. Catamaran has a market cap of $10.0 billion and is part of the health care sector. Shares are up 1.6% year to date as of the close of trading on Tuesday. Currently there are 16 analysts that rate Catamaran a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Catamaran as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, compelling growth in net income and growth in earnings per share. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Catamaran Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Humana ( HUM) is down $0.59 (-0.7%) to $84.59 on light volume. Thus far, 299,479 shares of Humana exchanged hands as compared to its average daily volume of 1.7 million shares. The stock has ranged in price between $84.57-$85.64 after having opened the day at $85.18 as compared to the previous trading day's close of $85.18.

Humana Inc., a health care company, offers insurance products and health and wellness services that incorporate an integrated approach to lifelong well-being. The company operates in three segments: Retail, Employer Group, and Health and Well-Being Services. Humana has a market cap of $13.3 billion and is part of the health care sector. Shares are up 24.1% year to date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Humana a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Humana as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, attractive valuation levels and increase in stock price during the past year. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Humana Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 4 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

China Slashes Auto Import Tariffs as Trump's Trade Push Gets Big Early Win

China Slashes Auto Import Tariffs as Trump's Trade Push Gets Big Early Win

Global Stocks Ease as Investors Focus on Dollar, Oil, Italy After US-China Truce

Global Stocks Ease as Investors Focus on Dollar, Oil, Italy After US-China Truce

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Replay: Jim Cramer on Tariffs, the Market Rally, Caterpillar and Micron

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: When Planning for Retirement, Don't Underestimate Your Life Span

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes

Video: Here's What May Come Next for Theranos Founder and CEO Elizabeth Holmes